ABOUT PRECIGEN
Great Science.
Greater Cause.
Precigen is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases.
Our Mission
Precigen’s mission is to discover, develop and commercialize next generation gene and cell therapies focused in immuno-oncology, autoimmune disorders, and infectious diseases.
Our Vision
Precigen’s vision is to develop life-saving and cost-conscious therapies utilizing our cutting-edge therapeutic and platform technologies for patients with unmet medical need.
Management
Precigen Leadership
Helen Sabzevari, PhD
President and CEO
Rutul R. Shah
Chief Operating Officer
Phil Tennant
Chief Commercial Officer
Harry Thomasian Jr.
Chief Financial Officer
Douglas E. Brough, PhD
SVP, Head of Research
Bryan T. Butman, PhD
SVP, Head of CMC
Steven Harasym
VP, Head of Investor Relations
Amy R. Lankford, PhD
SVP, Head of Clinical Operations and Regulatory Affairs
Donald Lehr, JD
Chief Legal Officer
Jeffrey Perez, JD
SVP, Intellectual Property Affairs
Rob Russell
VP, Head of Human Resources
Board of Directors
Randal J. Kirk
Executive Chairman
Nancy H. Agee
Director
Cesar L. Alvarez
Director
Steven R. Frank
Director
Vinita D. Gupta
Director
Fred Hassan
Director
Jeffrey B. Kindler
Director
Helen Sabzevari, PhD
Director
James S. Turley
Lead Independent Director